Black Di­a­mond turns down an open stretch of R&D high­way, head­ed to a show­down with onco­genes

As one of the lead sci­en­tists in­volved in the de­vel­op­ment of Tarce­va, David Ep­stein had plen­ty of op­por­tu­ni­ty to con­sid­er the many ways in which can­cer can evade a drug and kill pa­tients.

For the last 4 years, Ep­stein has been qui­et­ly work­ing away at the prob­lem, and he’s tak­en a turn down a stretch of R&D high­way which he be­lieves can lead to a full pipeline of new can­cer drugs that can broach that is­sue for par­tic­u­lar sub­sets of pa­tients. 

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN